California SB 122: What It Means for Companies

California recently enacted SB 122, which represents a significant expansion of the state’s sales and use tax framework as it applies to digital products, including prewritten computer software delivered electronically and software accessed remotely, including most SaaS and cloud-based arrangements. Under the existing California sales and use tax framework, sales and use tax has generally applied to transactions involving tangible personal property. Persons engaged in the business of rendering services have historically been treated as consumers, not sellers, of tangible personal property used incidentally in rendering those services, and sales and use tax applied to the purchase of such tangible property by such service providers. Because California did not historically include electronically delivered software or SaaS in the definition of digital goods, effective January 1, 2027, the enactment of SB 122 marks a significant development for any company that sells into or buys from California, with meaningful downstream effects across sectors.Continue reading

University of Arizona and Gila River Health Care Launch Nation’s First MD-Granting Medical School Branch within a Tribal Nation

On August 18, 2028, the University of Arizona and Gila River Health Care (GRHC), the Gila River Indian Community’s tribally operated healthcare system, announced a long-term partnership to establish the nation’s first MD-granting medical school branch located on the lands of a sovereign Tribal Nation.Continue reading

TIME Magazine Names The University of Arizona Center for Innovation Among Top Business Incubators

 

August 18, 2026 (Tucson, Ariz.)- The University of Arizona Center for Innovation (UACI) was recognized as one of America’s Best Incubators & Accelerators in 2026, as published by TIME Magazine, securing national recognition for its success in helping entrepreneurs launch and grow innovative science and technology companies. The ranking spotlights the United States’ most effective entrepreneurial programs that deliver the greatest value and measurable outcomes for early-stage companies.Continue reading

Definium Therapeutics Announces Positive Topline Results from Phase 3 Voyage Study of DT120 ODT in Generalized Anxiety Disorder

Study met primary and all key secondary efficacy endpoints

Participants receiving DT120 ODT achieved a statistically significant reduction in Hamilton Anxiety Rating Scale (HAM-A) score, with a placebo-adjusted change of 5.4 points from baseline at Week 12 (p<0.0001, Cohen’s d=0.81)

DT120 ODT was generally well tolerated, with a safety profile consistent with prior clinical experience

Company to host webcast today at 8:00 am EDT

Continue reading